INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
Search

All disclosures

Every ingested record across SEC Form 4, 13F, House PTRs and Robinhood Chain, searchable by ticker, name or wallet address.

Results

Data sources
SEC Form 42h ago
House PTR2h ago
SEC 13F1h ago
Robinhood Chain1h ago

Results

26,453 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
19
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$187K
4,064 sh
Feb 2, 2026Feb 4, 2026
Page 513 of 662
← PrevNext →
traded Feb 2, 2026
+2d
SEC Form 4

Evidence

19
MD
Moore Alexander D.Director
PLTRPalantir Technologies Inc.
Open-market sale · 10b5-1 plan
SELL$186K
1,233 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

18
HC
Howse CurtisSee remarks
SYFSynchrony Financial
Open-market sale · 10b5-1 plan
SELL$3.80M
52.6K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

17
MC
Malabre Richard CSVP, Chief Accounting Officer
AKBAAkebia Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$50K
36.1K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

17
MC
Malenka Robert C.Director
MPLTMapLight Therapeutics, Inc.
Open-market sale
SELL$18
1 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

16
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$133K
576 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

16
SM
Stetz MattiasChief Operating Officer
RSIRush Street Interactive, Inc.
Open-market sale · 10b5-1 plan
SELL$353K
20.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

16
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$197K
850 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

16
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$202K
878 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

16
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$140K
600 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

13
SJ
Schafer JoshuaCCO
ZVRAZEVRA THERAPEUTICS, INC.
Open-market sale · 10b5-1 plan
SELL$97K
10.5K sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

13
SM
Sharma ManishChief Strategy & Services Ofcr
ACNAccenture plc
Open-market sale · 10b5-1 plan
SELL$25K
98 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

13
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$3,744
16 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

13
WS
Wampler Kira SchererDirector
DOCSDoximity, Inc.
Open-market sale · 10b5-1 plan
SELL$75K
2,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

13
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$18K
80 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

12
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$34K
736 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

11
HK
Holleran KevinDirector, President and CEO
HAYWHayward Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$841K
52.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

11
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$27K
600 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

10
RM
Rucci Carolyn M.SVP, Chief Legal Officer
AKBAAkebia Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$35K
25.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

10
MC
Malabre Richard CSVP, Chief Accounting Officer
AKBAAkebia Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$19K
13.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

10
RM
Rucci Carolyn M.SVP, Chief Legal Officer
AKBAAkebia Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$23K
16.8K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

10
RM
Rucci Carolyn M.SVP, Chief Legal Officer
AKBAAkebia Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$38K
27.5K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

10
AL
Alpern Paul LVP and General Counsel
AIPArteris, Inc.
Open-market sale · 10b5-1 plan
SELL$77K
5,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
FD
Feierstein Matthew DavidPresident
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$121K
10.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
FD
Feierstein Matthew DavidPresident
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$102K
9,280 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

8
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$8,830
200 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

8
GS
Gummadi SuryaPresident - Americas
CTSHCOGNIZANT TECHNOLOGY SOLUTIONS CORP
Open-market sale · 10b5-1 plan
SELL$144K
1,728 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

8
OO
Okupe OluyemiChief Financial Officer
HIMSHims & Hers Health, Inc.
Open-market sale · 10b5-1 plan
SELL$139K
5,262 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

6
FD
Feierstein Matthew DavidPresident
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$108K
10.0K sh
Feb 4, 2026Feb 4, 2026
traded Feb 4, 2026
+0dSEC Form 4

Evidence

6
RR
Remer Eric RichardDirector, Chief Executive Officer
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$159K
14.7K sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

6
FD
Feierstein Matthew DavidPresident
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$8,388
720 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

5
SC
Saldanha CraigChief Product Officer
YELPYELP INC
Open-market sale · 10b5-1 plan
SELL$33K
1,200 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
VV
Vultaggio VincentPAO and PFO
ZNTLZentalis Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$6,477
2,540 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

3
RR
Remer Eric RichardDirector, Chief Executive Officer
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$20K
1,700 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

3
RR
Remer Eric RichardDirector, Chief Executive Officer
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$30K
2,797 sh
Feb 4, 2026Feb 4, 2026
traded Feb 4, 2026
+0dSEC Form 4

Evidence

1
BM
Barrett David MichaelDirector, Chief Executive Officer
EXFYExpensify, Inc.
Open-market sale · 10b5-1 plan
SELL$44K
30.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

1
VV
Vultaggio VincentPAO and PFO
ZNTLZentalis Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$1,398
556 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

1
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$75K
381 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

1
SN
Sieffert Kristen NPresident
FOAFinance of America Companies Inc.
Open-market sale · 10b5-1 plan
SELL$17K
750 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$7,449
39 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence